EGFR and neoplasm: When combined with gefitinib, metformin can activate the AMPK and epidermal growth factor receptor (EGFR) pathways to synergistically inhibit the growth of BC; when combined with pirubicin, AMPK activation is enhanced, and RNA synthesis is inhibited, which increases tumor suppression.